Literature DB >> 22904318

The antibodies against the computationally designed mimic of the glycoprotein hormone receptor transmembrane domain provide insights into receptor activation and suppress the constitutively activated receptor mutants.

Ritankar Majumdar1, Reema Railkar, Rajan R Dighe.   

Abstract

The exoloops of glycoprotein hormone receptors (GpHRs) transduce the signal generated by the ligand-ectodomain interactions to the transmembrane helices either through direct hormonal contact and/or by modulating the interdomain interactions between the hinge region (HinR) and the transmembrane domain (TMD). The ligand-induced conformational alterations in the HinRs and the interhelical loops of luteinizing hormone receptor/follicle stimulating hormone receptor/thyroid stimulating hormone receptor were mapped using exoloop-specific antibodies generated against a mini-TMD protein designed to mimic the native exoloop conformations that were created by joining the thyroid stimulating hormone receptor exoloops constrained through helical tethers and library-derived linkers. The antibody against the mini-TMD specifically recognized all three GpHRs and inhibited the basal and hormone-stimulated cAMP production without affecting hormone binding. Interestingly, binding of the antibody to all three receptors was abolished by prior incubation of the receptors with the respective hormones, suggesting that the exoloops are buried in the hormone-receptor complexes. The antibody also suppressed the high basal activities of gain-of-function mutations in the HinRs, exoloops, and TMDs such as those involved in precocious puberty and thyroid toxic adenomas. Using the antibody and point/deletion/chimeric receptor mutants, we demonstrate that changes in the HinR-exoloop interactions play an important role in receptor activation. Computational analysis suggests that the mini-TMD antibodies act by conformationally locking the transmembrane helices by means of restraining the exoloops and the juxta-membrane regions. Using GpHRs as a model, we describe a novel computational approach of generating soluble TMD mimics that can be used to explain the role of exoloops during receptor activation and their interplay with TMDs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904318      PMCID: PMC3464559          DOI: 10.1074/jbc.M112.355032

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  The ectodomain of the luteinizing hormone receptor interacts with exoloop 2 to constrain the transmembrane region: studies using chimeric human and fly receptors.

Authors:  Shinya Nishi; Koji Nakabayashi; Brian Kobilka; Aaron J W Hsueh
Journal:  J Biol Chem       Date:  2001-11-26       Impact factor: 5.157

2.  Two-stage polymerase chain reaction protocol allowing introduction of multiple mutations, deletions, and insertions, using QuikChange site-directed mutagenesis.

Authors:  Wenyan Wang; Bruce A Malcolm
Journal:  Methods Mol Biol       Date:  2002

3.  A hydrophobic cluster in the center of the third extracellular loop is important for thyrotropin receptor signaling.

Authors:  Maren Claus; Holger Jaeschke; Gunnar Kleinau; Susanne Neumann; Gerd Krause; Ralf Paschke
Journal:  Endocrinology       Date:  2005-09-08       Impact factor: 4.736

4.  Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity.

Authors:  S C Ho; J Van Sande; A Lefort; G Vassart; S Costagliola
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

5.  A free carboxylate oxygen in the side chain of position 674 in transmembrane domain 7 is necessary for TSH receptor activation.

Authors:  S Neumann; G Krause; S Chey; R Paschke
Journal:  Mol Endocrinol       Date:  2001-08

6.  Pleiotropic effects of substitutions of a highly conserved leucine in transmembrane helix III of the human lutropin/choriogonadotropin receptor with respect to constitutive activation and hormone responsiveness.

Authors:  H Shinozaki; F Fanelli; X Liu; J Jaquette; K Nakamura; D L Segaloff
Journal:  Mol Endocrinol       Date:  2001-06

7.  Molecular dynamics force probe simulations of antibody/antigen unbinding: entropic control and nonadditivity of unbinding forces.

Authors:  B Heymann; H Grubmüller
Journal:  Biophys J       Date:  2001-09       Impact factor: 4.033

Review 8.  Thyrotropin receptor mutations as a tool to understand thyrotropin receptor action.

Authors:  P Wonerow; S Neumann; T Gudermann; R Paschke
Journal:  J Mol Med (Berl)       Date:  2001-09-12       Impact factor: 4.599

9.  The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design.

Authors:  M Zhang; K P Tong; V Fremont; J Chen; P Narayan; D Puett; B D Weintraub; M W Szkudlinski
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

10.  Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.

Authors:  Cédric Blanpain; Jean-Marie Vanderwinden; Josef Cihak; Valérie Wittamer; Emmanuel Le Poul; Hassan Issafras; Manfred Stangassinger; Gilbert Vassart; Stefano Marullo; Detlef Schlndorff; Marc Parmentier; Matthias Mack
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

View more
  1 in total

1.  Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

Authors:  Susanne Neumann; Christine C Krieger; Marvin C Gershengorn
Journal:  Eur Thyroid J       Date:  2020-11-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.